Organon & Co. Discontinues Development of Endometriosis Drug After Phase 2 Study Fails Primary Efficacy Endpoint

Reuters
07/02
Organon & Co. Discontinues Development of Endometriosis Drug After Phase 2 Study Fails Primary Efficacy Endpoint

Organon & Co., a global healthcare company specializing in women's health, has announced results from their Phase 2 ELENA proof-of-concept study. The study evaluated the investigational candidate OG-6219, an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor, in patients with endometriosis-related pain. The trial did not meet its primary efficacy endpoint, as OG-6219 failed to demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Consequently, Organon plans to discontinue the clinical development program for OG-6219. The study was a randomized, double-blind, placebo-controlled, global multi-center trial involving pre-menopausal women aged 18 to 49 with surgically diagnosed endometriosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250702870387) on July 02, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10